

[Volume 21]

# Mirae Asset Minutes

## Biweekly strategy meeting recap

### Top stories

Pharma/Biotech (Samsung Biologics & LigaChem Biosciences)

Transportation (Korean Air)

# [Summary] Continue to focus on stocks with solid earnings

## 🎯 Top stories

### Pharma/Biotech (1)

Seung-min Kim

- Deal activity in the pharma/biotech sector tends to pick up in 4Q (activity generally increases from Oct. to Jan.); Fed rate cuts also bode well for biotech firms.
- Our top pick is [Samsung Biologics](#) with a target price of W1,350,000 (recently raised from W1,100,000). We significantly increased our valuation of the CDMO business.
- The CMO unit is faring well, as evidenced by major order wins (e.g., recently disclosed W1.7tr contract). The order environment remains highly favorable, with big pharma firms increasingly turning to outsourcing to respond to the rise of new modalities. The firm also stands to benefit from the Biosecure Act. Valuation could rise further once the ramp-up of Plant 5 accelerates.

### Pharma/Biotech (2)

Mihwa Seo

- We added [LigaChem Biosciences \(LigaChem\)](#) to our list of top picks. We recently raised our target price on the stock to W170,000 (from W86,000).
- While demand for ADC candidates continues to increase, many ADC players have already been acquired by big pharma companies, leaving few independent ADC-focused companies in the market.
- We see potential for additional large-scale licensing deals for the company's preclinical candidates, following the recently disclosed agreement with Ono Pharmaceutical (Oct. 10; worth US\$0.7bn).
- The repeated failures of competing Trop2 ADC candidates in clinical trials have raised expectations for LigaChem's Trop2 ADC.

### Transportation

Jay JH Ryu

- International passenger traffic in 1Q-3Q24 returned to pre-pandemic levels for the first time amid a rebound in long-haul demand and strong short-haul demand. Due to limited supply, cargo rates should remain stable despite slowing volume growth.
- Our top pick is [Korean Air](#) with a target price of W30,000. Asiana Airlines is expected to be incorporated as a subsidiary in Dec.
- The Asiana merger will place Korean Air among the 10 largest airlines globally. We foresee synergies, including stronger long-haul operations and enhanced operational efficiency. The stock is trading at a P/B of 0.9x; shares are likely to climb once merger uncertainties are removed.

## 🏆 Top picks

SK Hynix	NAVER	Shift Up	Samsung Biologics <sup>New</sup>	LigaChem <sup>New</sup>
HD Hyundai Electric <sup>New</sup>	LG Energy Solution	Hyundai Rotem	Korean Air <sup>New</sup>	Samsung Securities
	Hyosung Heavy <sup>Removed</sup>	Classys <sup>Removed</sup>	Hyundai Motor <sup>Removed</sup>	Hugel <sup>Removed</sup>

# [Summary] Continue to focus on stocks with solid earnings

## Investment ideas

- Fed rate cut expectations have continued to retreat; even two 25bp cuts by year-end are not fully priced in. Despite this, strong earnings reports from big banks, Netflix, Tesla, and others have buoyed US equities, with the Nasdaq approaching its all-time high set in Jul.
- Nvidia shares hit a new all-time high following news that Blackwell GPUs are sold out for the next 12 months (boosting earnings expectations). However, share performances have varied across other global semiconductor names. TSMC shares hit a record high on solid 3Q24 earnings, while ASML shares fell to a yearly low on an earnings shock. Intel shares remain weak, while AMD shares are moving sideways.
- In Korea, SK Hynix shares have rebounded since mid-Sep., but shares of Samsung Electronics (SEC) have weakened further, weighing on the KOSPI market. (SEC accounts for around 15% of the KOSPI's market cap.)
- However, we expect funds moving out of SEC to flow into other sectors and companies. In particular, the healthcare, defense, and power equipment sectors (which are displaying consistent earnings growth) should maintain solid momentum despite the KOSPI's weakness.
- For our top 10 picks, we added Samsung Biologics, LigaChem, HD Hyundai Electric, and Korean Air while excluding Hugel, Classys, Hyundai Motor (HMC), and Hyosung Heavy Industries. In the pharma/biotech/medtech space, we recently raised our target prices for both Samsung Biologics and LigaChem. In the power equipment sector, we replaced Hyosung Heavy Industries with HD Hyundai Electric (which reported decent 3Q24 results, helping to dispel uncertainties). Meanwhile, Korean Air looks undervalued relative to earnings, and we expect the stock to re-rate higher once the Asiana Airlines merger is completed.

## Stocks to watch (in addition to our top 10 picks)

- Samsung Fire & Marine (Samsung F&M): The company has been leveraging its capital strength to lower premiums, thus gaining market share. We believe it has the potential to secure a dominant position in the non-life insurance market.
- Hyundai Glovis: A long-term PCTC contract with a group affiliate is up for renewal, raising expectations for a sizable rate hike. In addition, non-affiliate volume is likely to expand thanks to the partnership with BYD, leading to mix improvements.




## New findings

- Deal activity in the pharma/biotech sector tends to pick up in 4Q. Looking at quarterly trends for M&As and licensing contracts worth over US\$300mn during the past three years, the highest activity was seen in 4Q23, followed by 1Q23, 4Q22, and 4Q21. Activity generally increases from Oct. to Jan. of the following year.
- The Fed lowered rates by 50bps in Sep. For biotech companies, lower interest rates reduce the discount rates used in DCF valuations, leading to higher valuations. This creates an incentive for big pharma companies to acquire biotech firms before rates fall further. Against this backdrop, we expect biotech M&A deals to increase in 4Q24.
- M&As in 4Q24 are likely to boost small/mid-cap US biotech stocks, positively affecting the KOSDAQ pharma index.


## Key charts

**M&As and licensing deals worth over US\$300mn by quarter**



Source: Evaluate, Mirae Asset Securities Research

**M&As and licensing deals worth over US\$300mn by month**



Source: Evaluate, Mirae Asset Securities Research

## Top pick

- For 3Q24, Samsung Biologics reported non-consolidated revenue of W1.07tr (+21% YoY; 10% above consensus), operating profit of W444.7bn (+17% YoY; 5% above consensus), and OP margin of 41.7% (-1.6%p YoY). Quarterly revenue surpassed W1tr for the first time, driven by the full operation of Plants 1, 2, and 3, the ramp-up of Plant 4, and favorable FX.
- After recently securing a W1.7tr contract, the company raised its full-year revenue growth guidance to 15-20% YoY (from 10-15% YoY).
- We recently raised our target price to W1,350,000 (from W1,100,000), which is based on the sum of the values of the CDMO business (W85.7tr; vs. W70.1tr previously) and Samsung Bioepis (W8.9tr; vs. W8.4tr previously).
- If the company secures additional large-scale orders, the ramp-up of capacity at Plant 5 will likely accelerate. Notably, big pharma companies are increasingly turning to outsourcing contracts to respond to diversification in modalities.

## Key charts


### 3Q24 review

(Wbn, %, %p)

	3Q23	2Q24	3Q24P			Growth	
			Preliminary	Consensus	Diff.	YoY	QoQ
Revenue	882.7	810.2	1,067.10	968.7	10.2	20.9	31.7
OP	381.6	329.2	444.7	424.1	4.9	16.5	35.1
OP margin	43.2	40.6	41.7	43.8	-2.1	-1.6	1.0
NP	283	272.6	323.5	345.2	-6.3	14.3	18.7
Net margin	32.1	33.6	30.3	35.6	-5.3	-1.7	-3.3

Note: Under non-consolidated K-IFRS  
Source: QuantiWise, Mirae Asset Securities Research

### Samsung Biologics: Annual new orders and market cap trend



Source: Dart, Mirae Asset Securities Research




## 💡 New findings

- ADCs are an emerging class of cancer treatments designed to selectively target and eliminate cancer cells.
- ADCs have gained increasing attention due to their efficacy and targeted actions, particularly after the success of Daiichi Sankyo's Enhertu (blockbuster drug released in 2019). Since 2020, major pharma firms such as Gilead, Pfizer, AbbVie, Johnson & Johnson, and Genmab have consistently pursued M&As with ADC specialists. Licensing deals to secure ADC candidates have also continued to increase.
- While demand for ADC candidates continues to increase, many ADC players have been acquired by big pharma companies, leaving few independent ADC-focused companies in the market.


## 📊 Key charts

### ADC market poised to grow to US\$31.7bn by 2030



Source: Evaluate, Mirae Asset Securities Research

### Acquisitions of ADC players by big pharma companies



Source: Mirae Asset Securities Research

## Top pick

- We see potential for additional large-scale licensing deals for LigaChem's preclinical candidates, following the recently disclosed agreement with Ono Pharmaceutical (Oct. 10; worth US\$700mn). The deal with Ono Pharmaceutical is meaningful as it marks the firm's first package deal (pipeline + platform).
- The repeated failures of competing Trop2 ADC candidates (Gilead's Trodelvy and Daiichi Sankyo's Dato-DXd) in clinical trials have raised expectations for LigaChem's Trop2 ADC. LigaChem licensed this candidate to Janssen in 2023; if Janssen exercises its option, milestones could reach US\$220mn.
- The continued demand for ADC candidates combined with the shrinking supply of available assets makes LigaChem well-positioned for future deal opportunities, especially given its proven technology and track record. We recently raised our target price to W170,000.


## Key charts

### LigaChem's strategy: Increased focus on package deals

#### Business Strategy Shift

LCB prioritizes high-value product deals over platform deals.

- Expediting asset development with our proprietary LBG linker and ConjuALL platform technology to extend the lead over latecomers.
- Elevating ADC product value through innovative modalities, while also developing Best-In-Class and First-In-Class ADCs.
- Multi-Target Package deals, combining platform and products deal, our new licensing model



Source: LigaChem, Mirae Asset Securities Research

### LigaChem: Licensing agreements

	Date	Partner	Pipeline	Milestones (Wbn)
Candidates	8/15	Fosun	LCB14 (HER2-MMAF)	20.8
	5/20	Iksuda	LCB73 (CD19-pPBD)	278.4
	10/20	CStone	LCB71 (ROR1-pPBD)	409.9
	12/20	Pyxis	LCB67 (DLK1-MMAE)	325.5
	12/21	Iksuda	LCB14 (HER2-MMAF)	1,186.4
	12/23	Janssen	LCB84 (Trop2-MMAE)	2,245.8
	10/24	Ono	LCB97 (L1CAM-ADC)	943.4
Platform	3/19	Takeda	ADC platform (3 linkers)	454.8
	6/21	Iksuda	ADC platform (6 linkers/toxins)	920.0
	11/21	Sotio	ADC platform (5)	1,212.7
	12/22	Amgen	ADC platform (5)	1,605.0
	10/24	Ono	ADC platform (undisclosed)	Undisclosed

Source: LigaChem, Mirae Asset Securities Research




## 💡 New findings

- In 1Q-3Q24 (cumulative), international passenger traffic was up 1.3% from the same period in 2019, returning to pre-COVID-19 levels for the first time.
- Demand on short-haul routes (especially Japan) has remained strong, and long-haul demand (US, Europe, etc.) rebounded during the long Chuseok holiday in Sep.
- While passenger traffic from China remains 19.1% below the 2019 level, solid demand for package tours during the National Day holiday (Oct. 1-7) could boost 4Q24 earnings.
- Air freight rates are likely to remain stable; despite slowing volume growth, limited supply should support profitability.


## 📊 Key charts

### Changes in international/transit passenger traffic vs. 2019



Source: Incheon International Airport, Mirae Asset Securities Research

### Weekly air freight rate trends



Source: TAC Index, Mirae Asset Securities Research





## Top pick

- The completion of the Asiana Airlines merger looks imminent, with relevant authorities expected to grant final approvals by end-Oct./early-Nov; Asiana Airlines is expected to be incorporated as a subsidiary in Dec.
- Based on a simple sum of Asiana Airlines and Korean Air, the merger should place Korean Air among the 10 largest airlines globally. We also foresee synergies, including stronger long-haul operations and enhanced operational efficiency.
- While Korean Air's debt ratio should rise after the merger, its cash position should enable a quick stabilization in financial structure.
- Limited supply is supporting air freight rates, while cease-fire talks in the Middle East are helping to ease upward pressure on oil prices. All in all, we expect earnings to remain solid going forward.
- The stock is still trading below a P/B of 1x, reflecting merger-related uncertainties and slowing cyclical momentum.


## Key charts

### Breakdown of post-merger fleet

	Model	Korean Air	Asiana Airlines	Total
Wide-body	A330-200/300	21	15	36
	A350	-	15	15
	A380	5	6	11
	B747	8	-	8
	B767	-	1	1
	B777-200/300	34	9	43
	B787-8/9/10	17	-	17
Narrow-body	A220	10	-	10
	A321	-	12	12
	A321-200N	12	10	22
	B737-800/900	20	-	20
	B737 Max 8	5	-	5
	<b>Passenger aircraft (total)</b>	<b>132</b>	<b>68</b>	<b>200</b>
Cargo	B767F	-	1	-
	B747-8F	7	11	7
	B747-400F	4	-	4
	B777F	12	-	12
<b>Cargo aircraft (total)</b>	<b>23</b>	<b>12</b>	<b>23</b>	
<b>Total</b>		<b>155</b>	<b>68</b>	<b>223</b>

Source: CAPA, Mirae Asset Securities Research

### Global airline rankings based on RPKs



Note: As of 2019

Source: IATA, Mirae Asset Securities Research

# Biweekly strategy meeting minutes

Top story A Top 10 pick

Sector	Analyst	Sector comments	Top picks	Stock-specific comments
Energy	Jinho Lee	<ul style="list-style-type: none"> <li>- Renewables: Wait-and-see approach likely to prevail until the US election; the Trump trade is gaining momentum; once the election is over, earnings expectations will likely be the key driver</li> <li>- Solar PV: While the overall market remains sluggish, Chinese stocks recently surged on the government's establishment of a price floor for solar modules and rumors of a power supply cap to reduce oversupply</li> <li>- Wind power: Companies in the domestic wind power value chain are likely to post solid 3Q24 results relative to other renewable energy players; after the US election, CS Wind's stock will likely rise on the back of its robust 2025 earnings outlook</li> </ul>	<p>[Short term] CS Wind</p> <p>[Medium term] Hanwha Solutions</p>	<p><b>CS Wind</b></p> <ul style="list-style-type: none"> <li>- Investment points: 1) removal of uncertainty over CS Wind Offshore's earnings thanks to successful price hike negotiations; 2) robust onshore wind earnings; 3) the Harris trade; and 4) rate cut expectations</li> </ul> <p><b>Hanwha Solutions</b></p> <ul style="list-style-type: none"> <li>- Investor sentiment could recover depending on the final results of antidumping/countervailing duty investigations (to be announced by year-end); investment points include: 1) business portfolio expansion in 2H24; and 2) a pickup in US module prices arising from tariff hikes</li> </ul>
Oil Refining/ Chemicals	Jinho Lee	<ul style="list-style-type: none"> <li>- Oil refining: Refining margins appear to have undershot and should recover on heating demand (ahead of winter) and China's economic stimulus; oil refiners are likely to post sizable losses for 3Q24, slightly missing consensus</li> <li>- Chemicals: Share price volatility is increasing, with China stimulus momentum having yet to materialize; with earnings visibility still limited and oil prices picking up, a conservative stance is warranted</li> </ul>	<p>[Short term] S-Oil</p> <p>[Medium term] S-Oil</p>	<p><b>S-Oil</b></p> <ul style="list-style-type: none"> <li>- Tepid earnings expectations for 3Q24 appear to be priced in; refining margins and oil prices are likely to rise on improved economic activity in the US/China (amid interest rate cuts and stimulus measures) and stronger demand for kerosene/diesel ahead of winter; historically low valuation (P/B of 0.7x)</li> </ul>
Defense/ Aerospace	Dong-ho Jeong	<ul style="list-style-type: none"> <li>- During a visit to Korea, the Polish president reaffirmed his commitment to strengthening defense cooperation between the two countries and said that K9/Chunmoo systems (W5tr) currently under conditional contracts would be procured without loans from Korea; a follow-up K2PL contract (W6-7tr) is set to be signed on Nov. 11</li> <li>- In 2025, export destinations are likely to expand to the US, the Middle East, and Southeast Asia</li> <li>- 3Q24 earnings season kicks off in late Oct.; we expect solid results, as earnings will likely be higher in 2H than in 1H; we favor Hyundai Rotem and Hanwha Aerospace; KAI also deserves attention, as its 3Q24 OP will likely beat the consensus thanks to one-off gains; the domestic defense sector's 12-month forward P/E stands at 19.2x, close to the historical average</li> </ul>	<p>[Short term] <b>Hyundai Rotem</b></p> <p>[Medium term] <b>Hyundai Rotem</b></p>	<p><b>Hyundai Rotem</b></p> <ul style="list-style-type: none"> <li>- 3Q24 OP to reach W122bn, 6% above consensus, thanks to a pickup in the progress rate of K2 "gap filler" deliveries to Poland and margin improvement in the rail solutions division</li> <li>- MSCI inclusion is highly likely (review and rebalancing set for Nov. 7 and Nov. 25, respectively)</li> <li>- We expect a follow-up contract with Poland for 180 additional K2PL tanks (consensus: W6-7tr) to be signed on Nov. 11; share performance to hinge on the contract value; if a contract for the remaining 640 units (for local production) is subsequently signed, concerns over a lull in revenue in 2026 would ease</li> <li>- The fourth round of K2 mass production (W1.9tr) is likely to be announced by end-2024; export deal with Romania for main battle tanks (50 units in the first round; W1.3tr) should take shape in 2025; valuation remains attractive at 12-month forward P/E of 15.1x (vs. defense sector avg. of 19.2x)</li> </ul>

# Biweekly strategy meeting minutes

Top story A Top 10 pick

Sector	Analyst	Sector comments	Top picks	Stock-specific comments
Construction/ Building Materials	Ki Ryong Kim	<ul style="list-style-type: none"> <li>- Shares remain weak despite the Oct. base rate cut, due to the BOK's still somewhat hawkish stance and financial regulators' efforts to rein in household debt growth</li> <li>- The government reversed a previous decision to restrict policy-backed loans aimed at low-income households, saying that it would continue to provide support for low-income, non-speculative homebuyers while managing household loan growth</li> <li>- 3Q24 earnings season is underway; expectations are limited due to housing cost ratio issues, concerns over unsold homes, etc.</li> </ul>	<p>[Short term] Samsung E&amp;A (prev. GS E&amp;C)</p> <p>[Medium term] GS E&amp;C (prev. Samsung E&amp;A)</p>	<p><b>Samsung E&amp;A</b></p> <ul style="list-style-type: none"> <li>- 3Q24 OP (W203.9bn; +32.9% YoY) beat the consensus by 10%, but shares fell 7.1% due to concerns over reduced orders from affiliates and the absence of hydrocarbon orders (new orders totaled only W0.6tr in 3Q24 vs. W10.9tr in 1H24)</li> <li>- In the hydrocarbon segment, potential order wins this year include the Qatar RLP project (US\$300mn), the Malaysia SAF project (US\$1bn), and the UAE Taziz methanol project (US\$1.5bn); additional order wins are also likely to materialize at the upcoming UAE ADIPEC 2024 event (Nov. 4-7)</li> <li>- The recent pullback looks excessive, given expectations for shareholder returns and hydrocarbon orders; the stock is trading at a 2024F P/B of only 0.83x, but valuation discount vs. global peers (2.16x) is likely to narrow going forward</li> </ul> <p><b>GS E&amp;C</b></p> <ul style="list-style-type: none"> <li>- 3Q24F OP of W88.9bn (+47.7% YoY), 5% above consensus</li> <li>- Earnings, financials, and orders are all improving; if the sale of GS Inima is completed, improvement in company-wide financials will likely accelerate</li> </ul>
Power Equipment	Yunju Cho	<ul style="list-style-type: none"> <li>- Shares of GE Vernova hit fresh highs after a strong 3Q24 earnings report; power equipment EBITDA margin exceeded 10% (surpassing that of the power division), and power equipment orders continued expanding (while the gas turbine order backlog remained at typical levels); management presented a rosy outlook, with orders from hyperscalers starting to increase and an investment super-cycle beginning</li> <li>- After announcing a US\$1.5bn investment in new transmission development on Oct. 3, the US DOE on Oct. 18 selected 38 projects for nearly US\$2bn in grid resilience funding; investment will enable nearly 300 miles of new transmission lines and provide upgrades to more than 650 miles of existing lines</li> <li>- During an annual oversight hearing, Korea's Minister of Trade, Industry and Energy said that incentives to prioritize power grid construction projects (which have been delayed) are under review</li> </ul>	<p>[Short term] Hyosung Heavy Industries</p> <p>[Medium term] <b>HD Hyundai Electric</b></p>	<p><b>Hyosung Heavy Industries</b></p> <ul style="list-style-type: none"> <li>- 3Q24 preview: In-line results likely for the heavy industries business (revenue of W828bn and OP of W96bn); W80bn in deferred revenue from 2Q24 likely to be recognized; rising mix of exports in the order backlog also likely had positive effects; watch pace of margin improvement in the heavy industries business and potential one-off expenses in construction</li> </ul> <p><b>HD Hyundai Electric</b></p> <ul style="list-style-type: none"> <li>- 3Q24 results were decent, with revenue of W789bn (+14% YoY; 5% below consensus) and OP of W164bn (+92% YoY; in line); seasonal factors and weakness in US-bound distribution equipment weighed on earnings, but core products (power equipment) and the key North American market remained solid overall; effects of expanded capacity at domestic/US facilities (completed in 3Q24) are likely to materialize from 2025</li> <li>- Ample cash holdings thanks to robust profits; first quarterly dividend since spin-off set at W1,100</li> </ul>

# Biweekly strategy meeting minutes

Top story A Top 10 pick

Sector	Analyst	Sector comments	Top picks	Stock-specific comments
Transportation	Jay JH Ryu	<ul style="list-style-type: none"> <li>- The SCFI showed bearish/flat movements throughout Oct. before jumping 123p in the week ending Oct. 25 (the first rebound in nine weeks); strong gains were seen on European and Middle Eastern routes, while secondary routes also saw a broad recovery</li> <li>- Delays to US railway operations and congestion at East Coast ports (due to the dockworkers' strike) likely offset downward pressure on freight rates, but it is too early to say whether the downtrend has reversed</li> <li>- Bulk carrier market remains subdued despite China's stimulus announcement; stimulus for real estate and manufacturing/infrastructure is smaller than expected, dampening hopes for a rebound in iron ore demand</li> <li>- Air freight rates continue to stabilize; despite a cyclical slowdown in volume growth, limited supply is likely to prop up profitability</li> </ul>	<p>[Short term] <b>Korean Air</b></p> <p>[Medium term] Hyundai Glovis</p>	<p><b>Korean Air</b></p> <ul style="list-style-type: none"> <li>- The Asiana Airlines merger looks imminent (Asiana expected to be incorporated as a subsidiary in Dec.); we expect the stock to benefit from reduced uncertainties and positive synergies</li> <li>- While Korean Air will need to act quickly to address a rise in debt ratio after the merger, its high profitability should enable a rapid stabilization in financial structure; mileage integration plans need to be presented within six months of the merger (1H25)</li> </ul> <p><b>Hyundai Glovis</b></p> <ul style="list-style-type: none"> <li>- A long-term PCTC contract with a group affiliate is up for renewal; a sizable rate hike is likely</li> <li>- Non-affiliate volume is likely to expand amid partnership with BYD, leading to mix improvements</li> <li>- Likely to enjoy "value-up" momentum following the announcement of its dividend policy (payout ratio of at least 25%/dividend increase of at least 5% YoY)</li> </ul>
Utilities	Jay JH Ryu	<ul style="list-style-type: none"> <li>- KEPCO raised industrial-use electricity rates by an average of 9.7%; while general-use rates were frozen, profitability is still set to improve, as the rate hike was the second-largest in the firm's history and industrial electricity accounts for more than half of consumption</li> <li>- Any further rate increase through year-end or in 1H25 seems unlikely, but residential and other electricity rates could be raised later, depending on the size of cumulative losses and investment needs</li> <li>- Gas utility stocks reacted positively to news regarding East Sea gas field development (Blue Whale project), including the selection of SLB to analyze rock/gas composition and the selection of S&amp;P as an investment advisor; however, we believe investors should wait until the project's viability is confirmed (following the results of exploration drilling)</li> </ul>	<p>[Short term] POSCO Int'l</p> <p>[Medium term] KEPCO</p>	<p><b>POSCO International</b></p> <ul style="list-style-type: none"> <li>- Authorities are discussing a regulatory framework for the Blue Whale project; share price momentum could increase depending on the results of exploration drilling in Dec.</li> <li>- Earnings from Myanmar gas field project continue to improve; likely to continue "value-up" efforts backed by solid cash flow</li> </ul> <p><b>KEPCO</b></p> <ul style="list-style-type: none"> <li>- The stock surged over 8% during intraday trading on Oct. 23 following electricity rate hikes; but the rebound appears to be coming to an end, as residential rates were frozen and the likelihood of further rate increases is limited through 1H25</li> <li>- Expectations for profitability improvement remain intact, backed by lower oil prices and mix improvements</li> </ul>

# Biweekly strategy meeting minutes

Top story A Top 10 pick

Sector	Analyst	Sector comments	Top picks	Stock-specific comments
Mobility	Chang-min Lee	<ul style="list-style-type: none"> <li>- Lotte Rental and SOCAR are scheduled to announce 3Q24 earnings on Nov. 5 and Nov. 12, respectively</li> <li>- Both firms are likely to report earnings improvements (vs. 1H24) thanks to seasonal demand, an easier comparison for used car sales, and cost control; at both firms, visibility on profit improvements is likely to increase as used car sales gradually resume in 2025</li> </ul>	<p>[Short term] SOCAR</p> <p>[Medium term] SOCAR</p>	<p><b>SOCAR</b></p> <ul style="list-style-type: none"> <li>- 3Q24 preview: Revenue likely expanded YoY, while OP likely swung to black on the reallocation of long-term rental (SOCAR Plan) cars to short-term car-sharing services to meet peak-season demand; that said, OP is likely to miss the consensus due to weaker-than-expected peak-season effects</li> <li>- In 2H24, the firm is making efforts to capture growing demand from foreign tourists (e.g., partnership with a global online travel agency and establishment of a SOCAR station in Jeju)</li> <li>- Used car sales to resume in 2025, sharply boosting profitability (5,000-8,000 units with an avg. age of four years)</li> </ul>
Autos	Jinsuk Kim	<ul style="list-style-type: none"> <li>- HMC/Kia missed 3Q24 OP consensus estimates due to one-off warranty expenses (excl. one-offs, OP was in line at HMC and above consensus at Kia); Hyundai Mobis beat OP consensus by 37%; HL Mando missed OP consensus due to a one-off item</li> <li>- Although HMC did not announce shareholder return measures related to the listing of its Indian subsidiary and could see increased volatility ahead of the US election, the stock remains our top medium/long-term pick due to its solid earnings outlook for 2025, the W4tr worth of share buybacks scheduled for 2025-27, and the likelihood of additional shareholder returns</li> <li>- Hyundai Mobis remains our top short-term pick, given the module/core parts division's swing to profitability and the potential announcement of increased shareholder returns at the CEO Investor Day event (Nov. 19); AMPC eligibility in 4Q24 is also positive</li> </ul>	<p>[Short term] Hyundai Mobis (prev. Hyundai Motor)</p> <p>[Medium term] Hyundai Motor</p>	<p><b>Hyundai Mobis</b></p> <ul style="list-style-type: none"> <li>- OP beat the consensus by 36%, with module/core parts swinging to a profit; A/S margins remained elevated</li> <li>- ASP hikes/mix improvements and settlement gains anticipated through 4Q; the firm is also expected to be eligible for the AMPC in 4Q; expectations are intact for CEO Investor Day</li> </ul> <p><b>Hyundai Motor</b></p> <ul style="list-style-type: none"> <li>- 3Q24 review: OP missed consensus by 8% (in line excl. one-off warranty expenses); other key variables were solid, but the company did not announce shareholder return measures related to the listing of the Indian subsidiary (disappointing market expectations); still, HMC remains our top medium/long-term pick given: 1) likely growth in US market share in 2025 driven by competitive pricing and new HEV models; 2) a likely acceleration in BEV sales growth in the US in 2025 supported by new model releases/subsidies; and 3) the W4tr worth of buybacks scheduled for 2025-27 and likelihood of additional shareholder return measures related to the Indian subsidiary</li> </ul>

# Biweekly strategy meeting minutes

Top story A Top 10 pick

Sector	Analyst	Sector comments	Top picks	Stock-specific comments
Cosmetics/ Apparel	Songyi Bae	<ul style="list-style-type: none"> <li>- Expectations for below-consensus 3Q24 results at some companies weighed on sector-wide sentiment</li> <li>- However, demand from non-China markets remains strong; as of Oct. 20, preliminary exports to the US/Japan already reached 95% of the total export value in Oct. 2023 (with makeup exports already surpassing total exports in Oct. 2023)</li> <li>- Preliminary exports of skin care products (to all markets) have also exceeded total exports in Oct. 2023; in particular, skin care product exports to China resumed growth for the first time in eight months, soaring 31.7% compared to total exports in Oct. 2023</li> </ul>	<p>[Short term] Cosmecca Korea (prev. F&amp;F)</p> <p>[Medium term] Cosmecca Korea</p>	<p><b>Cosmecca Korea</b></p> <ul style="list-style-type: none"> <li>- Benefiting from export growth at customers</li> <li>- The company still has ample available capacity (while rivals are facing capacity constraints)</li> <li>- Orders from domestic customers with export-oriented business models are growing steadily; profitability is likely to rise sharply on operating leverage effects from top-line growth</li> <li>- Valuation has fallen to a 12-month forward P/E of 13.9x amid an industry-wide pullback</li> </ul>
Retail	Songyi Bae	<ul style="list-style-type: none"> <li>- Consumption indicators are recovering at a slow pace; The Oct. CSI rose only modestly to 101.7p (+1.7p MoM)</li> <li>- In 3Q24, unfavorable weather (heavy rainfall in Jul. and prolonged heat) likely dampened foot traffic and winter item sales; companies' accelerated entry into online channels also likely weighed on earnings</li> <li>- Earnings likely to miss consensus overall; take a defensive approach, focusing on firms with limited earnings downside; we prefer convenience store plays</li> </ul>	<p>[Short term] BGF Retail</p> <p>[Medium term] Shinsegae</p>	<p><b>BGF Retail</b></p> <ul style="list-style-type: none"> <li>- SSS growth likely recovered to 1% YoY in 3Q24; fixed cost pressures (arising from the increasing share of directly leased stores) are easing</li> <li>- OP likely grew YoY for the first time in four quarters, helped by the consolidation of BGF Networks (expected to consistently contribute around W2bn in quarterly OP)</li> </ul> <p><b>Shinsegae</b></p> <ul style="list-style-type: none"> <li>- 3Q24 results are likely to miss consensus due to weakness in the luxury and fashion categories (department stores) and an increased rent burden (airport duty-free stores)</li> <li>- Valuation remains attractive (12MF P/E of 6x); waiting for a recovery in department store SSS growth</li> </ul>
Medtech	Choong-hyun Kim, CFA	<ul style="list-style-type: none"> <li>- Aesthetic devices: Volatility increased as Bain was rumored to be selling its stake in Classys; if the rumor proves to be false, the situation could present a buying opportunity (as the valuation burden has eased); if Bain does sell, an accompanying tender offer would be the best scenario; if only Bain's stake is sold, the global capabilities of the buyer will be crucial; with the situation still unclear and earnings approaching, PharmaResearch is a safer short-term pick</li> <li>- Digital health: Expectations mounting for a potential collaboration between i-SENS and a global diabetes company; announcement likely to come after mid-Nov.</li> </ul>	<p>[Short term] PharmaResearch</p> <p>[Medium term] Classys</p>	<p><b>PharmaResearch</b></p> <ul style="list-style-type: none"> <li>- Solid earnings expected for 3Q24; global expansion story remains intact, with the company preparing to enter new markets (Taiwan, Mexico, and Europe) in 2025</li> </ul> <p><b>Classys</b></p> <ul style="list-style-type: none"> <li>- 3Q24 results likely to meet consensus, but sale rumors have heightened share volatility; while several scenarios could unfold, we advise focusing on the stock's reduced valuation burden</li> </ul>

# Biweekly strategy meeting minutes

Top story A Top 10 pick

Sector	Analyst	Sector comments	Top picks	Stock-specific comments
Pharma/Biotech	Seung-min Kim	<ul style="list-style-type: none"> <li>- Earnings season has kicked off; Samsung Biologics' CMO business is performing strongly, as evidenced by large-scale order wins (e.g., recently disclosed W1.7tr contract); the firm is also likely to benefit from the Biosecure Act in the medium/long term</li> <li>- Deal activity tends to pick up in 4Q; M&amp;As in 4Q are likely to boost small/mid-cap US biotech stocks, positively affecting the KOSDAQ pharma index</li> <li>- Licensing expectations remain intact for Alteogen and LigaChem (SC technology for ADCs) as well as OliX (obesity drug)</li> <li>- New drugs developed by domestic pharmas are showing results globally, led by Yuhan (milestones), SK Biopharmaceuticals (Xcopri), Celltrion (Zymfentra), and GC Biopharma (Alyglo)</li> </ul>	<p>[Short term] <b>Samsung Biologics</b> (prev. Chong Kun Dang)</p> <p>[Medium term] Chong Kun Dang (prev. Celltrion)</p>	<p><b>Samsung Biologics</b></p> <ul style="list-style-type: none"> <li>- 3Q24 review: Non-consolidated revenue of W1.07tr (+21% YoY; 10% above consensus), OP of W444.7bn (+17% YoY; 5% above consensus), and OP margin of 41.7% (-1.6%p YoY); quarterly revenue surpassed W1tr for the first time, driven by the full operation of Plants 1, 2, and 3, the ramp-up of Plant 4, and favorable FX</li> <li>- The firm raised its full-year revenue growth guidance to 15-20% YoY (from 10-15% YoY).</li> </ul> <p><b>Chong Kun Dang</b></p> <ul style="list-style-type: none"> <li>- The FDA's approval of Yuhan's lazertinib should highlight undervalued pharmas with out-licensing track records</li> <li>- Chong Kun Dang is one such company, having secured a US\$1.3bn (W1.7tr) deal with Novartis in 2023, including an up-front payment of W110bn</li> </ul>
Global Biotech	Mihwa Seo	<ul style="list-style-type: none"> <li>- Domestic pharma firms operating in the US (Hugel, GC Biopharma, etc.) likely saw strong revenue in 3Q24</li> <li>- IPOs of domestic biotech firms are on the rise; notably, DAC developer Orum Therapeutics, which is preparing for a KOSDAQ listing, has already sold a candidate to Bristol-Myers Squibb and signed a technology out-licensing deal with Vertex</li> <li>- Expectations are rising for additional out-licensing deals from other companies, including LigaChem and Alteogen</li> </ul>	<p>[Short term] Hugel</p> <p>[Medium term] <b>LigaChem Biosciences</b> (prev. Hugel)</p>	<p><b>Hugel</b></p> <ul style="list-style-type: none"> <li>- Hugel is making efforts to expand its filler business in Japan (e.g., presenting at this year's meeting of the Japanese Society of Aesthetic Dermatology)</li> <li>- 3Q24 preview: Revenue of W99.2bn (+17% YoY) and OP of W44.9bn (+30% YoY)</li> <li>- For Letybo, US export revenue was likely reflected starting in 3Q24, as shipments were made in Jul. and Sep.</li> </ul> <p><b>LigaChem Biosciences</b></p> <ul style="list-style-type: none"> <li>- The clinical failures of competing Trop2 ADC candidates have raised expectations for LigaChem's Trop2 ADC</li> <li>- We see potential for additional large-scale licensing deals for the company's preclinical candidates, following the recently disclosed agreement with Ono (worth up to W1tr).</li> <li>- Partner Iksuda announced positive clinical results for IKS012 (targeting FRA) at ENA 2024</li> </ul>

# Biweekly strategy meeting minutes

Top story A Top 10 pick

Sector	Analyst	Sector comments	Top picks	Stock-specific comments
Banks	Tae Joon Jeong, CFA	<ul style="list-style-type: none"> <li>- Banks' combined 3Q24 NP likely met the consensus but fell 8.2% QoQ due to decreases in both interest income (-2.1% QoQ) and non-interest income (-10% QoQ), leading to a 3.8% fall in net operating revenue</li> <li>- "Value-up" momentum appears to have peaked following 2Q24 earnings announcements, as banks have no room to boost shareholder returns further</li> <li>- With interest rate cuts underway, NIM and interest income will likely stall until the rate cut cycle ends</li> </ul>	<p>[Short term] KBFG</p> <p>[Medium term] KBFG</p>	<p><b>KB Financial Group</b></p> <ul style="list-style-type: none"> <li>- KBFG announced plans to enhance corporate value, including maintaining a minimum shareholder return ratio of 40% and fully returning excess capital (above 13.5% CET1) until the stock hits a P/B of 1x; the group aims to maintain its industry-leading shareholder return ratio</li> <li>- 3Q24 NP beat consensus and our estimate; non-interest income, SG&amp;A costs, and credit costs were better than expected, offsetting a sharper-than-expected decline in NIM</li> <li>- Its industry-leading shareholder return ratio should provide solid downside support to the stock</li> </ul>
Securities	Tae Joon Jeong, CFA	<ul style="list-style-type: none"> <li>- Regardless of the Value-Up Index, high-dividend stocks should come into focus as year-end approaches; stocks that pulled back on exclusion from the index have become more attractive as dividend plays</li> <li>- For 3Q24, the combined NP of securities firms likely met the consensus; weak brokerage was likely offset by a favorable rate environment and a recovery in PF</li> </ul>	<p>[Short term] <b>Samsung Securities</b></p> <p>[Medium term] <b>Samsung Securities</b></p>	<p><b>Samsung Securities</b></p> <ul style="list-style-type: none"> <li>- Expected dividend yield for 4Q24 (7.8%) is higher than the levels of peers and other financial players; we expect the stock to gain attention toward year-end, when dividend funds should increase positions in high-dividend plays</li> <li>- High shareholder return yield points to strong valuation appeal, which could serve as another source of share momentum</li> </ul>
Insurance	Tae Joon Jeong, CFA	<ul style="list-style-type: none"> <li>- At the upcoming fourth insurance reform meeting, regulators will likely focus on standardizing lapse rate assumptions for zero/low-surrender-value policies with the aim of preventing insurers from applying overly optimistic lapse rates in the absence of reliable historical data; if more conservative assumptions are standardized, insurers with high exposure to zero/low-surrender-value policies (particularly those with longer maturities) would likely see a significant drop in CSM; this would mainly affect second-tier non-life insurers</li> <li>- This potential reduction in CSM could put further pressure on K-ICS ratios, which are already declining due to changes in economic assumptions and falling interest rates; another layer of strain could come from the scheduled extension of the last observable point in 2025; in the end, insurers with weaker capital positions are expected to face significant challenges</li> </ul>	<p>[Short term] Meritz Financial Group</p> <p>[Medium term] Samsung Fire &amp; Marine (prev. Meritz Financial Group)</p>	<p><b>Meritz Financial Group</b></p> <ul style="list-style-type: none"> <li>- Meritz plans to enhance shareholder returns primarily through buybacks until it reaches a P/E of 10x (which seems likely to happen soon)</li> <li>- If the stock reaches a P/E of 10x before the completion of the W1tr share buyback program (scheduled to last through Mar. 2025), buyback activity could weaken</li> </ul> <p><b>Samsung Fire &amp; Marine</b></p> <ul style="list-style-type: none"> <li>- Ahead of potential industry restructuring, the firm is favorably positioned thanks to its strong capital base; we believe it could leverage its capital strength to lower premiums and increase coverage, thus securing a dominant market position based solely on price competitiveness</li> </ul>



# Biweekly strategy meeting minutes

Top story A Top 10 pick

Sector	Analyst	Sector comments	Top picks	Stock-specific comments
Semiconductors	Young-gun Kim	<ul style="list-style-type: none"> <li>- Based on data for the past month, TrendForce forecasts 2024 DRAM bit growth at 22%; notably, the projection was not revised downward (vs. the previous month's estimate); bit growth for legacy applications (PC, mobile, etc.) remains in the low teens</li> <li>- AI-driven momentum is likely to continue amid earnings announcements and capex guidance by big tech firms (starting this week); while IT set demand forecasts remain unchanged, relatively low overall growth points to continued polarization, with AI-related demand outpacing overall IT device/set demand</li> </ul>	<p>[Short term] <b>SK Hynix</b></p> <p>[Medium term] Samsung Electronics</p>	<p><b>SK Hynix</b></p> <ul style="list-style-type: none"> <li>- In 3Q24, SK Hynix recorded meaningful increases in the contributions of HBM chips (to more than 30% of DRAM revenue) and enterprise SSDs (to more than 60% of NAND revenue), cementing its status as a key player in the AI ecosystem and further justifying our target P/B (2.0x); we expect earnings to continue to expand in 4Q24, helping to sustain share price momentum into late 2024/early 2025</li> </ul> <p><b>Samsung Electronics</b></p> <ul style="list-style-type: none"> <li>- 3Q24 earnings were likely weak, but the Oct. 31 conference call could provide insights regarding the firm's strategic direction; a trading approach is recommended in the near term (we see a high likelihood that the company will pass quality tests for HBM3E products); from a medium/long-term perspective, we advise accumulating shares due to the stock's low valuation</li> </ul>
EV Batteries	Chuljoong Kim	<ul style="list-style-type: none"> <li>- Volatility is likely to rise around the election</li> <li>- Europe: Anti-China tariffs finalized at end-Oct.; focus on potential reinstatement of EV subsidies</li> <li>- US: A potential Trump victory is a risk, but a complete repeal of the IRA is unlikely</li> <li>- Tesla and GM provided positive guidance during their 3Q24 earnings calls, lifting sentiment on EV demand</li> <li>- Policy and price indicators are likely to be positive; we recommend a gradual accumulation strategy focused on cell makers and large-cap stocks</li> </ul>	<p>[Short term] <b>LG Energy Solution</b></p> <p>[Medium term] Samsung SDI</p>	<p><b>LG Energy Solution</b></p> <ul style="list-style-type: none"> <li>- Demand sentiment improving quickly (relative to peers) on positive guidance from Tesla and GM</li> </ul> <p><b>Samsung SDI</b></p> <ul style="list-style-type: none"> <li>- Despite the industry slowdown, Samsung SDI has secured additional customers while continuing to diversify its product portfolio</li> <li>- Valuation is relatively attractive (12MF P/B of 1.2x)</li> </ul>
Battery Equipment	Junseo Park	<ul style="list-style-type: none"> <li>- Pay attention to leaders in next-gen technologies (dry coating, ASSBs, continuous mixers, etc.)</li> <li>- The bankruptcy filing of a subsidiary of Sweden's Northvolt led to share price declines for the related value chain</li> <li>- Potential beneficiaries of LGES's new form factors deserve attention in 2H24</li> <li>- LGES is set to establish pilot lines using dry process equipment by end-2024 and apply dry processes to both cathode and anode production lines by end-2028</li> <li>- Dry process to help reduce cost of electrode fabrication (excl. the mixing process) by 17-30%</li> </ul>	<p>[Short term] People &amp; Technology</p> <p>[Medium term] People &amp; Technology</p>	<p><b>People &amp; Technology</b></p> <ul style="list-style-type: none"> <li>- Revenue and OP margin likely improved YoY in 3Q24; that said, expenses related to new businesses were likely booked</li> <li>- Order backlog has reached a record (W2.2tr); growth likely continued in 3Q24</li> <li>- A North American customer is set to place dry process orders by year-end; in talks to supply dry process equipment to additional overseas customers and domestic customers</li> <li>- Continuing to add new customers despite the slowdown in capacity expansion globally</li> </ul>

# Biweekly strategy meeting minutes

Top story A Top 10 pick

Sector	Analyst	Sector comments	Top picks	Stock-specific comments
Electrical/ Electronic Components	Junseo Park	<ul style="list-style-type: none"> <li>- Competition among smartphone component suppliers is growing amid mounting cost-cutting pressure at a key customer</li> <li>- Initial iPhone 16 sales in China (first three weeks) are 2% below the level for the previous model</li> <li>- iPhone 16 shipment forecast for 2H24 revised down to 84mn units; Oct. iOS update likely to help drive sales volume</li> <li>- Taiwanese IT suppliers reported revenue growth of 22% YoY for Sep., supported by solid demand from AI servers and the iPhone 16 series</li> </ul>	<p>[Short term] LG Electronics (prev. SEMCO)</p> <p>[Medium term] SEMCO (prev. LG Electronics)</p>	<p><b>LG Electronics</b></p> <ul style="list-style-type: none"> <li>- Potential inclusion in the Value-Up Index in 2H24 or 1H25</li> <li>- Indian subsidiary reported top-line growth of 15% YoY and NP growth of 28% YoY in 1H24</li> <li>- When the Indian unit goes public, proceeds should help fund higher shareholder returns and new business M&amp;As</li> <li>- Trading at a 2024F P/B of 0.8x; strong downside support</li> </ul> <p><b>Samsung Electro-Mechanics</b></p> <ul style="list-style-type: none"> <li>- 3Q24 preview: Slightly above-consensus results likely</li> <li>- Likely beneficiary of on-device AI adoption; MLCC content per device to increase sharply (Galaxy S25: +24% vs. S24) due to on-device AI adoption and enhanced APs</li> <li>- Inventories have decreased to around four weeks of supply; downstream MLCC inventories are also at stable levels</li> </ul>
Battery Metals/Materials	Yoojin Choi	<ul style="list-style-type: none"> <li>- Battery metals: Earnings season has begun for lithium and nickel suppliers; despite higher lithium sales volume (Albemarle, etc.), profits likely contracted QoQ due to falling prices; nickel profits likely stayed flat QoQ</li> <li>- Battery materials: Suppliers likely suffered OP declines due to downstream inventory adjustments and higher fixed costs; that said, we advise focusing on new customer acquisitions</li> </ul>	<p>[Short term] Daejoo Electronic Materials</p> <p>[Medium term] Advanced Nano Products</p>	<p><b>Daejoo Electronic Materials</b></p> <ul style="list-style-type: none"> <li>- 3Q24 preview: Revenue likely grew on increased SK On shipments; meanwhile, OP likely declined slightly QoQ</li> <li>- Set to retain dominant position for at least four to five years, aided by: 1) broader application of next-gen materials (from premium to mass-market EVs); 2) capacity expansion; and 3) commercialization of silicon oxide anode materials</li> </ul> <p><b>Advanced Nano Products</b></p> <ul style="list-style-type: none"> <li>- Earnings are likely to trend higher from 3Q24, led by CNT conductive additives; however, consolidated OP should reflect higher fixed costs due to the operation of US/Poland facilities</li> <li>- Positives include: 1) production/supply of additives for mass-market EV models; 2) capacity ramp-ups; and 3) leadership in single-walled CNT slurry production</li> </ul>
Internet	HeeSeok Lim	<ul style="list-style-type: none"> <li>- Ad spending is likely to increase amid the monetary easing cycle; display ad growth is expected to recover</li> <li>- Commerce uncertainties have eased; growth of Chinese platforms is slowing</li> <li>- NAVER: Display ad growth is accelerating following app upgrades; interest rate cuts are also positive; commerce/Japan uncertainties have eased (compared to in 1H); set to benefit from the Tmon/WeMakePrice issue</li> <li>- Kakao: All business units (except for message-based ads) to continue low growth; content weakness is likely to deepen, casting doubts over 2H24 earnings</li> </ul>	<p>[Short term] <b>NAVER</b></p> <p>[Medium term] <b>NAVER</b></p>	<p><b>NAVER</b></p> <ul style="list-style-type: none"> <li>- Low valuation (2025F P/E of 17x; bottom of range since 2016)</li> <li>- Downtrend in avg. time spent on the NAVER app came to a halt following the launch of in-feed ads; ad revenue was likely robust in 3Q24</li> <li>- The display ad business is poised to benefit if domestic advertisers increase spending amid interest rate cuts</li> <li>- Commerce uncertainties have eased (compared to in 1H24); the growth of Chinese cross-border shopping platforms is slowing, and the exits of rival platforms Tmon and WeMakePrice will likely support a GMV recovery</li> <li>- Japan-related uncertainties lifted following the firm's announcement that it will maintain its stake in Line Yahoo</li> </ul>

# Biweekly strategy meeting minutes

Top story A Top 10 pick

Sector	Analyst	Sector comments	Top picks	Stock-specific comments
Games	HeeSeok Lim	<ul style="list-style-type: none"> <li>- Global gaming market growth accelerating amid a recovery in content supply</li> <li>- Full-fledged adoption of generative AI helping to improve productivity and cost efficiency</li> <li>- Labor cost pressures easing at domestic gaming firms amid a conservative hiring trend</li> <li>- Companies with strong competitiveness in the rapidly growing subculture genre deserve attention; Shift Up is our top pick in the sector</li> <li>- Krafton i likely to post solid 3Q24 results on continued growth in both the PC and mobile game segments</li> </ul>	<p>[Short term] <b>Shift Up</b></p> <p>[Medium term] <b>Shift Up</b></p>	<p><b>Shift Up</b></p> <ul style="list-style-type: none"> <li>- Strong competitiveness in the quickly growing subculture genre</li> <li>- Rapid growth expected from 1H25, supported by <i>Goddess of Victory: Nikke's</i> geographical expansion (to China) and <i>Stellar Blade's</i> platform diversification (to PCs)</li> <li>- Earnings momentum to strengthen in 2H24, aided by the second anniversary update for <i>Goddess of Victory: Nikke</i></li> <li>- The company won a license for <i>Goddess of Victory: Nikke</i> in China; full revenue recognition likely to begin in 2Q25</li> </ul>
Telecom Services	Soojin Kim	<ul style="list-style-type: none"> <li>- Telcos to announce 3Q24 earnings in the second week of Nov. (Nov. 6 for SKT; Nov. 8 for both KT and LG Uplus)</li> <li>- The wireless segment likely delivered solid growth thanks to flagship smartphone releases</li> <li>- As competition eases and marketing costs stabilize at lower levels, companies with improving profits deserve attention</li> </ul>	<p>[Short term] KT</p> <p>[Medium term] SK Telecom</p>	<p><b>KT</b></p> <ul style="list-style-type: none"> <li>- Ongoing restructuring likely gave rise to one-off costs but should help boost profits over the medium/long term</li> <li>- Additional “value-up” policies likely (end-Oct. or early Nov.)</li> <li>- Likely to recognize one-off gain of W900bn related to the Gwangjin-gu development project in 2025; funds are likely to be used to expand shareholder returns</li> <li>- That said, with foreign ownership approaching the current cap (49%), further foreign buying will likely be limited</li> </ul> <p><b>SK Telecom</b></p> <ul style="list-style-type: none"> <li>- SKT’s “value-up” plans (unveiled on Oct. 24) include achieving ROE of 10% by end-2026 and distributing at least 50% of consolidated profit to shareholders; SKT also aims to increase the revenue share of AI businesses to 35% by end-2030</li> <li>- With SKT having been excluded from the Value-Up Index, its “value-up” plans appear centered on longer-term targets</li> <li>- The company reaffirmed its strategic focus on the AI business and profit improvement</li> </ul>
IT Services	Soojin Kim	<ul style="list-style-type: none"> <li>- 3Q24 earnings season kicks off with Samsung SDS and Hyundai AutoEver (Oct. 30)</li> <li>- 3Q24 earnings will likely be in line with consensus overall, as contracts typically increase in 3Q ahead of the peak season (4Q); that said, results should vary by firm depending on downstream market conditions</li> <li>- Increasing visibility on generative AI services</li> </ul>	<p>[Short term] Douzone Bizon (prev. Samsung SDS)</p> <p>[Medium term] Douzone Bizon (prev. Samsung SDS)</p>	<p><b>Douzone Bizon</b></p> <ul style="list-style-type: none"> <li>- Shares of Douzone Bizon have risen ahead of its earnings release (early Nov.), as its generative AI assistant OneAI was reported to have attracted more than 1,000 customers since its launch in Jun.; rapid customer base expansion is significant, as the service can induce customers to switch to cloud services and contribute to revenue growth going forward</li> <li>- For 3Q24, we estimate revenue at W101bn and OP at W21.3bn, in line with consensus; by year-end, the firm will likely garner increasing interest as a leading domestic generative AI player amid increasing visibility on global generative AI services</li> </ul>

# Appendix 1

## Important disclosures and disclaimers

### Two-year rating and TP history

Company	Date	Rating	TP (LOC)	Company	Date	Rating	TP (LOC)	
CS Wind (112610)	08/09/24	Buy	78,000		11/23/23	Buy	34,000	
	05/10/24	Buy	59,000		04/28/23	No Coverage		
	10/18/23	Buy	70,000		11/23/22	Buy	34,000	
					03/21/22	Hold	26,000	
Hanwha Solutions (009830)	07/26/24	Buy	35,000	GS E&C (006360)	08/28/24	Buy	28,000	
	07/05/24	Buy	39,000		07/29/24	Buy	24,000	
	05/27/24	Buy	45,000		02/01/24	Buy	21,000	
	05/16/24	Trading Buy	33,000		11/23/23	Buy	23,000	
	04/26/24	Trading Buy	28,000		04/28/23	No Coverage		
	02/23/24	Trading Buy	33,000		11/23/22	Trading Buy	26,000	
	01/12/24	Buy	51,000		07/11/22	Buy	44,000	
	11/23/23	Buy	46,000		HYOSUNG HEAVY (298040)	09/26/24	Buy	460,000
	11/01/23	Buy	40,000			HD Hyundai Electric (267260)	09/26/24	Buy
	07/31/23	Buy	45,000		04/24/24		Buy	300,000
	04/28/23	Buy	73,000		03/20/24		Buy	185,000
	02/17/23	Buy	60,000		02/16/24		Buy	150,000
	10/07/22	Buy	66,000		01/24/24		Buy	120,000
			11/27/23	Buy	107,000			
S-Oil (010950)	10/08/24	Buy	79,000	Korean Air (003490)	01/31/24	Buy	30,000	
	07/15/24	Buy	85,000		01/10/24	One year	32,000	
	04/26/24	Buy	89,000		01/10/23	Buy	32,000	
	01/29/24	Buy	104,000		11/04/22	Buy	35,000	
	10/30/23	Buy	87,000		08/17/22	One year		
	04/27/23	Buy	94,000		Hyundai Glovis (086280)	07/25/24	Buy	150,000
	01/19/23	Buy	114,000			07/01/24	Buy	150,059
	04/07/22	Buy	133,000			01/26/24	Buy	115,046
Hyundai Rotem (064350)	10/15/24	Buy	78,000	01/10/24		One year	125,050	
	07/29/24	Buy	65,000	01/10/23		Buy	125,050	
	04/01/24	Buy	48,000	04/29/22		Buy	135,053	
	09/20/23	Buy	37,000					
Samsung E&A (028050)	03/07/24	Buy	38,000					

# Appendix 1






Company	Date	Rating	TP (₩)	Company	Date	Rating	TP (₩)
POSCO International (047050)	07/26/24	Buy	65,000		04/29/24	Buy	350,000
	04/26/24	Buy	60,000		04/26/24	No Coverage	
	10/31/23	Buy	65,000		04/26/23	Buy	250,000
	04/27/23	Buy	35,000		10/24/22	Buy	220,000
	04/25/23	One year	33,000	Cosmecca Korea (241710)	08/13/24	Buy	120,000
	04/25/22	Buy	33,000		07/12/24	Buy	100,000
KEPCO (015760)	08/09/24	Buy	27,000	BGF Retail (282330)	08/02/24	Buy	150,000
	02/26/24	Trading Buy	27,000		01/16/24	Buy	180,000
	11/15/23	Hold	18,000		11/28/23	Buy	170,000
	02/28/23	Hold	20,000	Shinsegae (004170)	10/10/24	Buy	210,000
	02/25/23	One year	23,000		05/09/24	Buy	220,000
	02/25/22	Hold	23,000		01/17/24	Buy	210,000
					10/18/23	Buy	250,000
SOCAR (403550)	05/14/24	Buy	26,000	05/30/23	Buy	270,000	
	02/21/24	Buy	23,000	09/19/22	No Coverage		
	11/29/23	Buy	21,000	PharmaResearch (214450)	08/22/24	Buy	260,000
	11/28/23	No Coverage					
	08/09/23	Buy	21,000	Classys (214150)	10/18/24	Buy	74,000
	02/16/23	Buy	28,000		08/22/24	Buy	67,000
	11/29/22	Buy	23,000		05/13/24	Buy	60,000
			05/08/24		Buy	50,000	
			02/15/24		Buy	45,000	
Hyundai Mobis (012330)	10/28/24	Buy	330,000	11/08/23	Buy	48,000	
	07/29/24	Buy	310,000	08/14/23	Buy	42,000	
	04/29/24	Buy	320,000	05/25/23	Buy	32,000	
	04/26/24	No Coverage		05/11/23	Buy	30,000	
	01/29/24	Buy	280,000	02/16/23	Buy	25,000	
	07/28/23	Buy	295,000	05/11/22	Buy	23,000	
	04/25/23	One year	275,000	Samsung Biologics (207940)	10/22/24	Buy	1,350,000
	04/25/22	Buy	275,000				
Hyundai Motor (005380)	10/25/24	Buy	360,000				
	07/09/24	Buy	385,000				

# Appendix 1


Company	Date	Rating	TP (₩)	Company	Date	Rating	TP (₩)
Chong Kun Dang (185750)	01/30/24	One year	1,100,000	Samsung Fire & Marine (000810)	06/10/24	Buy	100,000
	01/30/23	Buy	1,100,000		07/15/24	Buy	460,000
	01/03/23	Buy	1,000,000		06/10/24	Buy	430,000
Hugel (145020)	01/22/24	Buy	160,000	03/30/23	No Coverage		
	08/31/23	Buy	104,978	09/23/22	Trading Buy		230,000
	02/06/23	Buy	114,521	SK Hynix (000660)	10/24/24	Buy	270,000
	02/07/22	Buy	109,344		07/25/24	Buy	260,000
LigaChem Biosciences (141080)	08/22/24	Buy	360,000		05/16/24	Buy	240,000
	10/25/24	Buy	170,000		04/26/24	Buy	220,000
KB Financial Group (105560)	05/29/24	Buy	86,000	03/05/24	Buy	200,000	
	07/08/24	Buy	110,000	12/29/23	Buy	173,000	
Samsung Securities (016360)	06/10/24	Buy	100,000	06/12/23	Buy	150,000	
	01/08/24	No Coverage		01/26/23	Buy	120,000	
	10/25/23	Buy	72,000	06/07/22	Buy	133,000	
	07/20/23	Buy	63,000	Samsung Electronics (005930)	05/16/24	Buy	110,000
	04/10/23	Buy	62,000		01/03/24	Buy	105,000
	02/03/22	No Coverage			07/10/23	Buy	90,000
	Meritz Financial Group (138040)	09/02/24	Buy		60,000	11/04/22	Buy
		08/12/24	Buy	55,000	06/07/22	Buy	84,000
07/03/24		Buy	51,000	LG Energy Solution (373220)	09/30/24	Buy	510,000
06/10/24		Buy	47,000		07/26/24	Buy	420,000
01/08/24		No Coverage			03/13/24	Buy	540,000
05/31/23		Buy	49,000		01/30/24	Buy	500,000
03/30/23		No Coverage		11/17/23	Buy	590,000	
11/23/22		Trading Buy	41,000	04/10/23	Buy	900,000	
06/15/22	Trading Buy	43,000	11/14/22	Buy	750,000		
Samsung SDI (006400)	09/19/24	Buy	120,000	05/31/22	Buy	670,000	
	07/15/24	Buy	110,000	10/04/24	Buy	530,000	
				08/20/24	Buy	440,000	

# Appendix 1

Company	Date	Rating	TP (₩)	Company	Date	Rating	TP (₩)
People & Technology (137400)	03/13/24	Buy	660,000	Advanced Nano Products (121600)	07/23/24	Buy	150,000
	01/31/24	Buy	520,000		12/30/10	One year	
	11/01/23	Buy	650,000	NAVER (035420)	07/23/24	Buy	135,000
	04/28/23	One year	1,100,000		05/26/22	One year	
	04/28/22	Buy	1,100,000	Shift Up (462870)	08/09/24	Buy	260,000
06/11/24	Buy	96,700	07/25/24		Buy	245,000	
05/30/24	Buy	84,000	07/08/24		Buy	240,000	
03/05/24	Buy	60,000	05/13/24		Buy	255,000	
11/13/23	Buy	80,000	05/03/24		Buy	290,000	
07/13/23	Buy	92,000	03/11/24		Buy	260,000	
07/29/22	Buy	76,500	02/02/24		Buy	310,000	
LG Electronics (066570)	07/03/24	Buy	150,000		08/07/23	Buy	290,000
	01/29/24	Buy	130,000		02/06/23	Buy	280,000
	11/28/23	Buy	140,000		11/08/22	Buy	250,000
	07/31/23	No Coverage		08/08/22	Buy	340,000	
	04/28/23	Buy	160,000	KT (030200)	09/11/24	Buy	95,000
	10/31/22	Buy	120,000		10/16/24	Buy	50,000
	06/30/22	Buy	150,000	10/25/23	One year	47,000	
Samsung Electro-Mechanics (009150)	07/03/24	Buy	200,000	10/25/22	Buy	47,000	
	11/28/23	Buy	190,000	SK Telecom (017670)	10/16/24	Buy	70,000
	07/31/23	No Coverage			07/19/24	Buy	67,000
	01/26/23	Buy	190,000		10/25/23	One year	76,000
	10/17/22	Buy	170,000	10/25/22	Buy	76,000	
Daejoo Electronic Materials (078600)	08/14/24	Buy	167,000	Douzone Bizon (012510)	08/06/24	Buy	80,000
					07/05/24	Buy	95,200




# Appendix 1





# Appendix 1



## Stock ratings

Buy	Expected 12-month performance: +20% or greater
Trading Buy	Expected 12-month performance: +10% to +20%
Hold	Expected 12-month performance: -10% to +10%
Sell	Expected 12-month performance: -10% or worse

## Sector ratings

Overweight	Expected to outperform the market over 12 months
Neutral	Expected to perform in line with the market over 12 months
Underweight	Expected to underperform the market over 12 months

Rating and TP history: Share price (—), TP (—), Not Rated (□), Buy (▲), Trading Buy (■), Hold (●), Sell (◆)

\* Our investment rating is a guide to the expected return of the stock over the next 12 months.

\* Outside of the official ratings of Mirae Asset Securities Co., Ltd., analysts may call trading opportunities should technical or short-term material developments arise.

\* The TP was determined by the research analyst through valuation methods discussed in this report, in part based on estimates of future earnings.

\* TP achievement may be impeded by risks related to the subject securities and companies, as well as general market and economic conditions.

# Appendix 1

## Ratings distribution and investment banking services

	Buy	Trading Buy	Hold	Sell
Ratings distribution	82.38%	10.23%	7.39%	0%
Investment banking services	84.21%	5.26%	10.53%	0%

\* Based on recommendations in the last 12-months (as of September 30, 2024)

## Disclosures

As of the publication date, Mirae Asset Securities Co., Ltd. and/or its affiliates own 1% or more of NAVER's shares outstanding.

As of the publication date, Mirae Asset Securities Co., Ltd. has acted as a liquidity provider for equity-linked warrants backed by shares of LG Electronics, Hyundai Glovis, KB Financial Group, KEPCO, SK Telecom, Samsung E&A, KT, NAVER, SK Hynix, Samsung Fire & Marine, Korean Air, Shinsegae, Hyundai Motor, Samsung Electronics, GS E&C, Samsung SDI, Samsung Electro-Mechanics, Hanwha Solutions, S-Oil, Hyundai Mobis, Samsung Biologics, LG Energy Solution as an underlying asset; other than this, Mirae Asset Securities has no other special interests in the covered companies.

As of the publication date, Mirae Asset Securities Co., Ltd. has been acting as an advisor to KEPCO

As of the publication date, Mirae Asset Securities Co., Ltd. is acting as a financial advisor to LigaChem Biosciences for its treasury share buyback and cancellation.

## Analyst certification

The research analysts who prepared this report (the "Analysts") are registered with the Korea Financial Investment Association and are subject to Korean securities regulations. They are neither registered as research analysts in any other jurisdiction nor subject to the laws or regulations thereof. Each Analyst responsible for the preparation of this report certifies that (i) all views expressed in this report accurately reflect the personal views of the Analyst about any and all of the issuers and securities named in this report and (ii) no part of the compensation of the Analyst was, is, or will be directly or indirectly related to the specific recommendations or views contained in this report. Mirae Asset Securities Co., Ltd. ("Mirae Asset Securities") policy prohibits its Analysts and members of their households from owning securities of any company in the Analyst's area of coverage, and the Analysts do not serve as an officer, director, or advisory board member of the subject companies. Except as otherwise specified herein, the Analysts have not received any compensation or any other benefits from the subject companies in the past 12 months and have not been promised the same in connection with this report. Like all employees of Mirae Asset Securities, the Analysts receive compensation that is determined by overall firm profitability, which includes revenues from, among other business units, the institutional equities, investment banking, proprietary trading, and private client divisions. At the time of publication of this report, the Analysts do not know or have reason to know of any actual, material conflict of interest of the Analyst or Mirae Asset Securities except as otherwise stated herein.

## Disclaimers

This report was prepared by Mirae Asset Securities, a broker-dealer registered in the Republic of Korea and a member of the Korea Exchange. Information and opinions contained herein have been compiled in good faith and from sources believed to be reliable, but such information has not been independently verified and Mirae Asset Securities makes no guarantee, representation or warranty, express or implied, as to the fairness, accuracy, completeness, or correctness of the information and opinions contained herein or of any translation into English from the Korean language. In case of an English translation of a report prepared in the Korean language, the original Korean language report may have been made available to investors in advance of this report.

The intended recipients of this report are sophisticated institutional investors who have substantial knowledge of the local business environment, its common practices, laws, and accounting principles, and no person whose receipt or use of this report would violate any laws or regulations or subject Mirae Asset Securities or any of its affiliates to registration or licensing requirements in any jurisdiction shall receive or make any use hereof.

This report is for general information purposes only and is not and shall not be construed as an offer or a solicitation of an offer to effect transactions in any securities or other financial instruments. The report does not constitute investment advice to any person, and such person shall not be treated as a client of Mirae Asset Securities by virtue of receiving this report. This report does not take into account the particular investment objectives, financial situations, or needs of individual clients. The report is not to be relied upon in substitution for the exercise of independent judgment. Information and opinions contained herein are as of the date hereof and are subject to change without notice. The price and value of the investments referred to in this report and the income from them may depreciate or appreciate, and investors may incur losses on investments. Past performance is not a guide to future performance. Future returns are not guaranteed, and a loss of original capital may occur. Mirae Asset Securities, its affiliates, and their directors, officers, employees, and agents do not accept any liability for any loss arising out of the use hereof.

Mirae Asset Securities may have issued other reports that are inconsistent with, and reach different conclusions from, the opinions presented in this report. The reports may reflect different assumptions, views, and analytical methods of the analysts who prepared them. Mirae Asset Securities may make investment decisions that are inconsistent with the opinions and views expressed in this research report. Mirae Asset Securities, its affiliates, and their directors, officers, employees, and agents may have long or short positions in any of the subject securities at any time and may make a purchase or sale, or offer to make a purchase or sale, of any such securities or other financial instruments from time to time in the open market or otherwise, in each case either as principals or agents. Mirae Asset Securities and its affiliates may have had, or may be expecting to enter into, business relationships with the subject companies to provide investment banking, market-making, or other financial services as are permitted under applicable laws and regulations.

No part of this document may be copied or reproduced in any manner or form or redistributed or published, in whole or in part, without the prior written consent of Mirae Asset Securities. For further information regarding company-specific information as it pertains to the representations and disclosures in this Appendix 1, please contact [compliance@miraeasset.us.com](mailto:compliance@miraeasset.us.com) or +1 (212) 407-1000.

# Appendix 1

## **Distribution**

**United Kingdom:** This report is being distributed by Mirae Asset Securities (UK) Ltd. in the United Kingdom only to (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), and (ii) high net worth companies and other persons to whom it may lawfully be communicated, falling within Article 49(2)(A) to (E) of the Order (all such persons together being referred to as "Relevant Persons"). This report is directed only at Relevant Persons. Any person who is not a Relevant Person should not act or rely on this report or any of its contents.

**United States:** Mirae Asset Securities is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This report is distributed in the U.S. by Mirae Asset Securities (USA) Inc., a member of FINRA/SIPC, to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6(b)(4) under the U.S. Securities Exchange Act of 1934, as amended. All U.S. persons that receive this document by their acceptance hereof represent and warrant that they are a major U.S. institutional investor and have not received this report under any express or implied understanding that they will direct commission income to Mirae Asset Securities or its affiliates. Any U.S. recipient of this document wishing to effect a transaction in any securities discussed herein should contact and place orders with Mirae Asset Securities (USA) Inc. Mirae Asset Securities (USA) Inc. accepts responsibility for the contents of this report in the U.S., subject to the terms hereof, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through Mirae Asset Securities. The securities described in this report may not have been registered under the U.S. Securities Act of 1933, as amended, and, in such case, may not be offered or sold in the U.S. or to U.S. persons absent registration or an applicable exemption from the registration requirements.

**Hong Kong:** This report is distributed in Hong Kong by Mirae Asset Securities (HK) Limited, which is regulated by the Hong Kong Securities and Futures Commission. The contents of this report have not been reviewed by any regulatory authority in Hong Kong. This report is for distribution only to professional investors within the meaning of Part I of Schedule 1 to the Securities and Futures Ordinance of Hong Kong (Cap. 571, Laws of Hong Kong) and any rules made thereunder and may not be redistributed in whole or in part in Hong Kong to any person.

**India:** This report is being distributed by Mirae Asset Capital Markets (India) Private Limited ("MACM") in India to the customers based in India and is personal information only for those authorised recipient(s). MACM is inter alia a Securities and Exchange Board of India ("SEBI") registered Research Analyst in India and is not registered outside India. MACM and Mirae Asset, Korea are group entities. MACM makes no guarantee, representation or warranty, express or implied, as to the fairness, accuracy, completeness or correctness of the information and opinions contained herein. The user assumes the entire risk of any use made of this information. This report has been provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipient must read the entire Appendix 1 to the report carefully for Important Disclosures & Disclaimers.

**All other jurisdictions:** Customers in all other countries who wish to effect a transaction in any securities referenced in this report should contact Mirae Asset Securities or its affiliates only if distribution to or use by such customer of this report would not violate applicable laws and regulations and not subject Mirae Asset Securities and its affiliates to any registration or licensing requirement within such jurisdiction.

# Mirae Asset Securities International Network

---

**Mirae Asset Securities Co., Ltd. (Seoul)**

One-Asia Equity Sales Team  
Mirae Asset Center 1 Building  
26 Eulji-ro 5-gil, Jung-gu, Seoul 04539  
Korea

Tel: 82-2-3774-2124

---

**Mirae Asset Securities (USA) Inc.**

810 Seventh Avenue, 37th Floor  
New York, NY 10019  
USA

Tel: 1-212-407-1000

---

**Mirae Asset Securities (Singapore) Pte. Ltd.**

6 Battery Road, #11-01  
Singapore 049909  
Republic of Singapore

Tel: 65-6671-9845

---

**Mirae Asset Investment Advisory (Beijing) Co., Ltd**

2401B, 24th Floor, East Tower, Twin Towers  
B12 Jianguomenwai Avenue, Chaoyang District  
Beijing 100022  
China

Tel: 86-10-6567-9699

---

**Ho Chi Minh Representative Office**

7F, Saigon Royal Building  
91 Pasteur St.  
District 1, Ben Nghe Ward, Ho Chi Minh City  
Vietnam

Tel: 84-8-3910-7715

---

**Mirae Asset Securities (HK) Ltd.**

Units 8501, 8507-8508, 85/F  
International Commerce Centre  
1 Austin Road West  
Kowloon  
Hong Kong  
Tel: 852-2845-6332

---

**Mirae Asset Wealth Management (Brazil) CCTVM**

Rua Funchal, 418, 18th Floor, E-Tower Building  
Vila Olimpia  
Sao Paulo - SP  
04551-060  
Brazil  
Tel: 55-11-2789-2100

---

**Mirae Asset Securities (Vietnam) LLC**

7F, Saigon Royal Building  
91 Pasteur St.  
District 1, Ben Nghe Ward, Ho Chi Minh City  
Vietnam

Tel: 84-8-3911-0633 (ext.110)

---

**Beijing Representative Office**

2401A, 24th Floor, East Tower, Twin Towers  
B12 Jianguomenwai Avenue, Chaoyang District  
Beijing 100022  
China

Tel: 86-10-6567-9699 (ext. 3300)

---

**Mirae Asset Capital Markets (India) Pvt Ltd**

1st Floor, Tower 4, Equinox Business Park,  
LBS Marg, Off BKC, Kurla (West), Mumbai - 400 070  
India

Tel: 91-22-62661300 / 48821300

---

**Mirae Asset Securities (UK) Ltd.**

41st Floor, Tower 42  
25 Old Broad Street,  
London EC2N 1HQ  
United Kingdom

Tel: 44-20-7982-8000

---

**PT. Mirae Asset Sekuritas Indonesia**

District 8, Treasury Tower Building Lt. 50  
Sudirman Central Business District  
Jl. Jend. Sudirman, Kav. 52-54  
Jakarta Selatan 12190  
Indonesia  
Tel: 62-21-5088-7000

---

**Mirae Asset Securities Mongolia UTsK LLC**

#406, Blue Sky Tower, Peace Avenue 17  
1 Khoroo, Sukhbaatar District  
Ulaanbaatar 14240  
Mongolia

Tel: 976-7011-0806

---

**Shanghai Representative Office**

38T31, 38F, Shanghai World Financial Center  
100 Century Avenue, Pudong New Area  
Shanghai 200120  
China

Tel: 86-21-5013-6392

---